Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...

European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...

Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...